Mana Mohan Mukherjee,
Nabamita Basu‡
and
Rina Ghosh*
Department of Chemistry, Jadavpur University, Jadavpur, Kolkata 700032, West Bengal, India. E-mail: ghoshrina@yahoo.com
First published on 27th October 2016
The development of a new glycosylation method for efficient stereoselective synthesis of β-gluco- and galactosides from their corresponding armed trichloroacetimidate donors mediated by 10 mole% of FeCl3 has been focused. FeCl3 has also been applied to a number of glucose, galactose, mannose and rhamnose based trichloroacetimidate donors with various protecting groups incorporated at the C-2-position to prepare a variety of disaccharides and trisaccharides with excellent 1,2-trans selectivity. FeCl3 can also modulate the 1,2-trans selectivity of the reaction of 2-O-alkylated gluco- and galacto-pyranosyl trichloroacetimidates with phenolic compounds leading to the generation of the corresponding β-O-aryl glycosides in excellent yield and selectivity. Apart from these the present methodology has been successfully utilized for double glycosylation and orthogonal glycosylation reactions along with its application in one-pot three component orthogonal glycosylation reactions for synthesis of a trisaccharide.
Stereocontrol in the absence of usual neighbouring O-acyl group participation is considerably more challenging. Many factors, such as steric hindrance of protecting groups, reaction solvent, and temperature can affect the stereochemical outcome of a glycosylation reaction, and these effects are typically difficult to predict for any given donor–acceptor pair. So, better methods to control stereoselectivity in the absence of neighbouring ester group participation are also needed.
On the other hand, β-O-aryl glycosides have been recently found to exhibit anti tumour, anti HIV and anti bacterial activities. β-O-Aryl glycoside formation is considered as a difficult task due to electron withdrawing power of the aromatic ring, the facile rearrangement of the resulting O-aryl glycosides to their corresponding C-aryl glycosides and steric hindrance from substituents on phenolic glycosyl acceptors;5 hence their stereo-controlled synthesis has become a challenging job.6 Glycosyl acetates, halides and trichloroacetimidates (TCA) have been used as donors in the formation of β-O-aryl glycosides.6 Glycosyl acetates usually provide the β-O-aryl glycosides with lower yields than trichloroacetimidates due to anomerization of both the glycosyl donor and the coupling product.6 The β-O-aryl glycosides can be formed in the glycosylation reaction by employing ester functionalities as the directing group at the C-2 position of glycosyl donors. In some cases, formation of orthoester side products and migration of the C-2-O-acyl functionality are also observed in the reaction.3,7
Since the first paper on Schmidt's glycosylation method was published in 1980,8a,b till date trichloroacetimidates have been among the most widely used glycosyl donors.8c Their popularity comes from their relative ease of synthesis by base-catalyzed addition of trichloroacetonitrile to the anomeric hydroxy group9 and their easy activation; it also opens up the scope for orthogonal glycosylation. The glycosyl trichloroacetimidate donors are generally activated by strong Lewis acids such as BF3·OEt2,8a TMSOTf,9a Tf2O,10 ZnBr2,11 NOBF4,12 Sm(OTf)3,13a LiClO4,14 LiOTf,15 or other systems like I2/Et3SiH,13b acid washed 4 Å molecular sieves,13c,d HClO4/SiO2,16 Amberlyst 15,17 AuCl3–phenylacetylene,18 etc.; many of these are however not without limitations.
In the last decade FeCl3 has drawn much attention of the researchers worldwide for its wide range of application in organic synthesis.23 Our strategy for 1,2-trans glycosylation was to exploit the ability of this first row transition metal-Lewis acids to direct glycosylation of trichloroacetimidate donor. The choice of FeCl3 was based on the presumption that, for glucose and galactose donors, like Pd a seven member cyclic chelate19,24 (b) may be the possibility involving electronically vacant metal center (Fe), α-imidate nitrogen and C-2-oxygen of glycosyl trichloroacetimidate donor (a) which in effect would block the α-face of the proposed TS (c) for the attacking incoming nucleophilic acceptor, so that ultimately it can result in β-glycoside (d), vide Fig. 1.
Our initial study was performed with 2,3,4,6-tetra-O-benzyl-D-glucopyranosyl trichloroacetimidate, 1 as the armed glycosyl donor and methyl 2,3,4-tri-O-benzoyl-α-D-glucopyranoside 2 as the acceptor. Upon treatment of these coupling partners in 1.2
:
1 molar ratio with 30 mole% FeCl3 at −5 °C to room temperature for 1 hour, the desired disaccharide 3 was isolated in 67% yield as a single β isomer. 1H-NMR spectrum showed one anomeric proton appearing at δ 4.55 ppm with J 8.0 Hz corresponding to the H′1 indicating 1,2-trans glycosylation. This was also corroborated by the appearance of peaks at δ 101.9 and 104.0 ppm, corresponding to the anomeric carbons C′1 and C1, respectively. Higher δ value of the reducing anomeric carbon, in spite of it having an α-stereochemistry is attributed to the deshielding caused by three benzoyl protections on this pyranoside ring. The result, as we presumed, was indeed interesting and encouraging too, as this was clearly implying the ability of FeCl3 to activate trichloroacetimidate stereoselectively in the presence of apparently silent spectator protecting group like O-benzyl or without assistance by the solvent.
As an initial effort for optimization of a standard procedure for glycosylation we applied different catalyst loading (of FeCl3) with variation in temperature and solvent, as well as few other catalysts too (Table 1). Finally we selected the most economically acceptable and efficient reaction condition as 10 mole% FeCl3 at −60 °C to room temperature and used the process for further studies.
| Entry | Catalyst (mole%) | Reaction temperature | Time | Yieldb | (α/β ratio)c |
|---|---|---|---|---|---|
a All reactions were carried out in DCM with 1.2 equiv. of donor.b Isolated yield.c 1H NMR ratio.d Using MeCN : DCM (1 : 2).e Using Et2O : DCM (1 : 1).f Using 99.99% FeCl3 of Sigma Aldrich.g Using β anomer of 1 as donor. |
|||||
| 1 | FeCl3 (30) | −5 °C to rt | 1 h | 67% | (β only) |
| 2 | FeCl3 (20) | −30 °C to rt | 45 min | 72% | (β only) |
| 3 | FeCl3 (30) | −60 °C to rt | 45 min | 83% | (β only) |
| 4 | FeCl3 (20) | −60 °C to rt | 45 min | 90% | (β only) |
| 5 | FeCl3 (10) | −60 °C to rt | 45 min | 96% | (β only) |
| 6 | FeCl3 (5) | −60 °C to rt | 45 min | 92% | (β only) |
| 7 | FeCl3 (10) | −80 °C to rt | 45 min | 94% | (β only) |
| 8 | FeCl3 (10) | −60 °C to rt | 45 min | 94% | (β only)d |
| 9 | FeCl3 (10) | −60 °C to rt | 45 min | 93% | (2 : 3)e |
| 10 | FeCl3 (10) | −60 °C to rt | 45 min | 94% | (β only)f |
| 11 | FeCl3 (10) | −60 °C to rt | 35 min | 93% | (β only)g |
| 12 | FeBr3 (30) | −50 °C to rt | 45 min | 59% | (1 : 9) |
| 13 | In(OTf)3 (30) | −50 °C to rt | 45 min | 62% | (β only) |
With an optimized reaction condition in hand we then set out to explore the scope of FeCl3 catalyzed 1,2-trans selective glycosylations. A variety of nucleophilic glycosyl acceptors incorporating various protecting groups like ether, isopropylidene ketals and benzylidene acetals were exemplified with glycosyl donor 1 (Table 2). Glycosyl acceptors with least reactive 4-OH, hindered tertiary alcohol like 1-adamentanol and sensitive diisopropylidene protection (4, 6 and 8, respectively) in reaction with 1 generated the corresponding disaccharides 5, 7 and 9 in excellent yields (entries 2, 3 and 4, Table 2), with notable β selectivity compared to the reported ones.13a,19b,c The structure of compound 7 (CCDC no. 1501233) was confirmed by its X-ray structure (Fig. 2).
| Entry | Donor | Acceptor | Product | Yieldb (α : β) |
Entry | Donor | Acceptor | Product | Yieldb (α : β) |
|---|---|---|---|---|---|---|---|---|---|
| a All reactions were carried out in dry DCM with 1.2 equiv. of donor at −60 °C to rt.b Isolated yield.c Use of glycosyl donor in 1.5 g scale.d Reaction was carried out at −5 °C to rt. | |||||||||
| 1 | ![]() |
![]() |
![]() |
96% β (89%)c | 6 | ![]() |
2 | ![]() |
95% β |
| 2 | 1 | ![]() |
![]() |
93% β | 7 | 12 | 4 | ![]() |
88% β |
| 3 | 1 | ![]() |
![]() |
94% β | 8 | 12 | ![]() |
![]() |
89% β |
| 9 | 12 | ![]() |
![]() |
90% β | |||||
| 4 | 1 | ![]() |
![]() |
85% β | 10 | ![]() |
4 | ![]() |
87% αd |
| 5 | ![]() |
8 | ![]() |
87% β | 11 | ![]() |
![]() |
![]() |
92% β |
The efficacy of the present procedure was further established when we examined this chemistry with 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl trichloroacetimidate 12; the armed donor is well known for its α-directive effect for 4 axial –OH group. Compared to other reported methods,25,26 we observed remarkable β selectivity when glycosylation reactions of 12 were performed with carbohydrate acceptors 2, 4, 15 and 17 having nucleophilic hydroxy group on C-6, C-4, C-3 and C-2 positions, respectively; irrespective of their position and reactivity, the corresponding desired disaccharides (13, 14, 16 and 18) were obtained in excellent yield and β selectivity (entries 6 to 9, Table 2).
The present method also responded efficiently under a scale-up (∼30 fold) condition when applied for preparation of 3 from reaction of 1 and 2 (entry 1, Table 2), thus opening up scope to apply this method for preparative purpose also. When 4,6-O-benzylidene-2,3-di-O-benzyl-α-D-glucopyranosyl trichloroacetimidate donor, 10 reacted with acceptor 8 the desired disaccharide 11 was obtained in 87% yield as β isomer; the reaction of it's galactose analogue 21 with acceptor 22 gave the β-disaccharide 23 in 92% yield (entries 5 and 11, respectively, Table 2). When armed D-mannopyranosyl trichloroacetimidate donor 19 was allowed to react with nucleophilic acceptor 4, the corresponding α-disaccharide 20 was obtained in high yield (entry 10, Table 2).
The other glycosyl trichloroacetimidate donor systems that needed to be exercised in FeCl3 catalyzed glycosylation protocol were those with C-2-O-acyl protecting donors. It is expected that ester functionality from C-2 position might control the formation of 1,2-trans through the usual neighbouring group participation. Glycosylation of donors 24, 27, 29, 32, 34, and 36 with a variety of glycosyl acceptors like 25, 30 and 2 separately (entries 1 to 6, Table 3) provided the corresponding 1,2-trans selective products 26, 28, 31, 33, 35 and 37.
To further demonstrate the efficacy of the glycosylation protocol, we set out to pursue a glycosylation reaction of donor 1 with a disaccharide acceptor 38, where we get the trisaccharide, 39 in 89% yield and as β anomer. It is to be noted here that the reported method using Pd(PhCN)2Cl2 + AgOTf produces the trisaccharide 39 in 71% yield with β
:
α = 12
:
1 anomeric ratio.19c Then we turned to a couple of double glycosylation of carbohydrate diol. Pair up of 4,6-glucopyranosyl diol 41 and phthalimide protected glucosamine donor 40, resulted with the desired trisaccharide 42 in 83% yield where as the same diol acceptor 41 reacted with the rhamnosyl donor 27 affording 81% of the desired trisaccharide 43 (Scheme 2).
Next, we turned our attention to apply the present protocol for the synthesis of β-aryl glycosides. FeCl3 catalyzed β-selective arylation was found effective for D-glucopyranosyl trichloroacetimidate donor 1 with a variety of electron-rich phenols (44, 46 and 50), and the corresponding desired glycosides 45, 47 and 51 were isolated in excellent yield and β-selectivity (entries 1, 2 and 4, Table 4). Similarly, tetra-O-benzyl-D-galactopyranosyl trichloroacetimidate substrate 12 was also examined under the standardized condition to react with different phenols 44, 53, and 55; in each case we found the corresponding desired β-O-aryl galactoside 52, 54 and 56 to be formed with promising result on the ground of yield and selectivity (entries 5 to 7, Table 4).
To explore further the applicability of this procedure we then chose a sterically hindered 2,6-dimethylphenol 48. Gratifyingly, this phenol acceptor 48 was able to couple with both donors 1 and 12 to provide the corresponding O-aryl glycosides 49 and 57, respectively with excellent yield and anomeric selectivity (entries 3 and 8, Table 4). It may be mentioned here that the reported coupling between phenol 48 and tetra-O-benzyl-D-glucothioglycoside donor affords the desired product 49 with excellent yield (90%) albeit with low selectivity (α
:
β = 2.6
:
1),27a whereas the sulfoxide approach gave 70% yield as a 2
:
1 mixture of α- and β-anomer.27b
After achieving a convenient synthetic route for 1,2-trans selective glycosylation with trichloroacetemidate donors, we also sought to verify the efficiency of the Lewis acidity of FeCl3 to promote thioglycoside activation in combination with NIS. For this purpose thioglycoside donors 58, 61, 63 and 66 were allowed to couple with benzyl N-(3-hydroxypropyl) carbamate 59 (entries 1 and 2, Table 5), 1-adamentanol 6 (entries 3 and 4, Table 5) and carbohydrate acceptor like 4 (entry 5, Table 5) to produce the corresponding glycosides 60, 62, 64, 65 and 67 in excellent respective yield and expected β-steroselectivity due to C-2 neighbouring group participation. A rare sugar derivative of D-rhamnose donor 68 was allowed to couple with similar acceptor 69 to give stereoselectively the desired disaccharide 70 in 91% yield (entry 6, Table 5). Reaction of mannosyl donor 71 with di-mannoside acceptor 72 produces the mannose trisaccharide 73 in 90% yield (entry 7, Table 5). These reactions thus prove the ability of FeCl3 to catalyse thioglycoside activation too, in combination with NIS and opens up the gateway for its further elaboration in orthogonal glycosylations.
Orthogonal glycosylation of trichloroacetimidate donors with thioglycosides pave the way for efficient streamline oligosaccharide assemblies.28 Activity of FeCl3 towards orthogonal glycosylation of trichloroacetimidate donors with thio glycoside acceptors have also been investigated there after (Table 6). Glycosylation with orthogonal trichloroacetimidate donor 1 and the glycosyl acceptor 74 bearing thiophenyl group at its anomeric position produced the corresponding β disaccharide 75 in 85% yield (entry 1, Table 6). Similar reaction between 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl trichloroacetimidate donor 10 and phenyl 2,3,6-tri-O-benzyl-1-thio-β-D-glucopyranoside 74 generated the desired β disaccharide 76 in 94% yield (entry 2, Table 6). Coupling of trichloroacetimidate donors 77, 80 and 83 separately with the thioglycoside acceptors 78 (entry 3, Table 6), 81 (entry 4, Table 6) and 84 (entry 5, Table 6), respectively produced the corresponding glycosides 79, 82 and 85 in 94%, 92% and 88% yield. Unexpectedly, the armed fucosyl TCA donor 83 produced selectively the corresponding α-glycoside, 85. This could be due to much high reactivity of 83, for which here the glycosylation reaction probably proceeds via formation of the corresponding oxonium ion intermediate rather than via the corresponding Fe-chelated TS. This might cause the anomeric selectivity in favour of the thermodynamic product, α-glycoside (85). All the reactions under Tables 1–6 clearly represent the applicability of FeCl3 in stereoselective glycosylation via trichloroacetemidate activation, thioglycoside activation in combination with NIS and also orthogonal glycosylation of the former in the presence of the thioglycoside acceptor.
Now, finally the efficacy of FeCl3 was exemplified for chain elongation, essential for oligosaccharide synthesis29 by one pot sequential glycosylation with trichloroacetimidate donor followed by thioglycoside activation (Scheme 3).
For this trichloroacetimidate donor 1 was allowed to react with 4-methylphenyl 2,3,4-tri-O-benzoyl-1-thio-β-D-glucopyranoside 86 at −60 °C to room temperature in the presence of 10 mole% FeCl3; after consumption of both of the starting materials (checked by TLC) and after an increase of the reaction temperature to 0 °C the acceptor 8 was injected followed by addition of NIS along with additional 10 mole% FeCl3. The reaction was complete within 15 minutes giving the trisaccharide 39 in 87% yield as β anomer (Scheme 3).
So far we have observed that glucose and galactose based trichloroacetimidate armed donors are activated by FeCl3 generating selectively 1,2-trans glycosides in reaction with a variety of glycosyl acceptors (Tables 2, 4 and 6). It is also interesting to note that the reaction of β-TCA donor with 2 under similar condition also produced the same product 3 in comparable yield and selectivity (entry 11, Table 1). Moreover, in situ anomerisation of each of α- or β-TCA in the presence of FeCl3 in CH2Cl2 solution could not also be established. These facts preclude the possibility of these reactions to proceed following SN2 like pathway. All these thus support our initial proposition of the reaction proceeding via a SN1 type mechanistic pathway through probably an initial formation of a 7-membered chelate in each case of the α- and β-TCA donor. Whereas the former chelate is attacked from the β-side of the carbocation intermediate by the incoming glycosyl acceptor (α-side being blocked, Fig. 1), but, for the more reactive β-TCA probably there is sufficient time lag between breaking of the β-C1–O bond of the donor and formation of the β-glycosidic bond so that the approach of the incoming nucleophile can be accommodated at the β-side, since the α-side is still blocked by the bulky pendant C2–O–[Fe]NCOCCl3 group. In the case of mannosyl donor (entry 10, Table 2) possibility of chelation of catalyst with C-1 and C-2 substituents in the reactant donor does not arise due to their 1,2-trans diaxial orientation. So here probably the reaction proceeds via usual intermediate oxocarbenium ion.30 It has already been reported that with greater number of degrees of freedom, a direct steric interaction between the 6-benzyloxy group and the aglycon is possible, and this interaction will predominate the formation of α-anomer over the β one.31 Moreover, the bulk of benzyloxy group at 4-position also restricts the conformational space allotted for 3-O-benzyl ether, which in turn might impinge on the conformation of 2-O-benzyl ether destabilizing the β anomer over the α one.31
To corroborate with the above we further planned to perform FeCl3 mediated glycosylation reactions (Table 7) using two other armed donors. Like the armed trichloroacetimidate donor 1 bearing C-2–OBn (Table 1), the first trichloroacetimidate donor having a C-2–OMe group 87 (entry 1, Table 7) in reaction with the glycosyl acceptor 2, generated the corresponding disaccharide 88 (entry 1, Table 7) with exclusive 1,2-trans or β-anomeric selectivity. This observation precludes the take part of the phenyl ring of the 2-O-benzyl protection during formation of the proposed TS (b or c, Fig. 1). Additional indirect endorsement in favour of the projected mechanistic pathway (Fig. 1) came from a glycosylation reaction of acceptor 15 utilising 2-deoxy glycosyl donor 89 (entry 2, Table 7) which afforded the corresponding glycoside 90 in 87% yield but with α-anomeric selectivity, as evidenced by NMR32 (1H- and 13C-) spectra. In the absence of 2-oxygen formation of TS (b) or (c) (Fig. 1) does not arise here. With the deoxy donor the reaction probably proceeds via formation of the usual oxonium ion intermediate.
O), 165.5 (C
O), 165.8 (C
O). HRMS (ESI-TOF): calculated for C62H60O14Na (M + Na) 1051.3881 found 1051.3882.
:
1) to afford the compound 5 in 93% β only as white solid,33 Rf 0.33 (80% CH2Cl2 in hexane); mp 84–85 °C (from hexane), lit.33 mp 88–89 °C, mp 79–81 °C (ether–hexane); [α]24D +22.8 (c 1.15, CHCl3); lit.33 [α]24D +22 (c 0.4 CHCl3); 1H NMR (CDCl3, 300 MHz): δ 3.34–3.38 (m, 2H), 3.41 (s, 3H, OCH3), 3.49–3.56 (m, 3H), 3.60–3.65 (m, 3H), 3.77 (bd, 1H, J = 10.9 Hz, BnH), 3.88–3.94 (m, 2H), 4.02 (t, 1H, J = 9.7 Hz), 4.41–4.48 (m, 4H, BnH), 4.59–4.68 (m, 4H, BnH), 4.77–4.95 (m, 7H, BnH, H1, H′1), 5.14 (d, 1H, J = 11.3 Hz, BnH), 7.23–7.49 (m, 35H, ArH). 13C NMR (CDCl3, 75 MHz): δ 55.3, 67.9, 69.1, 70.1, 73.4, 73.7, 74.8, 74.9, 75.2, 75.4, 75.6, 78.1, 78.9, 80.4, 82.8, 84.9, 98.5 (C′1), 102.5 (C1), 127.1, 127.3, 127.5, 127.6, 127.7, 127.8, 127.82, 128.02, 128.04, 128.08, 128.1, 128.3, 128.4, 128.5, 137.9, 138.3, 138.4, 138.6, 138.62, 138.7, 139.6. HRMS (ESI-TOF): calculated for C63H70O11Na (M + Na) 1025.4816 and found 1025.4814.
:
1) to afford the compound 7 (62.3 mg) in 94% β as white solid.19c Rf = 0.72 (hexane/ethyl acetate, 4/1). Mp 118–120 °C (from ethyl acetate, pet-ether), [α]24D +14.2 (c 0.96, CHCl3); 1H NMR (CDCl3, 300 MHz): δ 1.65 (bs, 6H), 1.83–1.93 (m, 6H), 2.17 (bs, 3H), 3.58 (dd, 1H, J = 3.6, 9.7 Hz), 3.60–3.72 (m, 2H), 3.80 (dd, 1H, J = 3.5, 10.5 Hz), 4.03–4.09 (m, 2H), 4.49 (d, 1H, J = 12.1 Hz, BnH), 4.51 (d, 1H, J = 9.6 Hz, BnH), 4.68 (t, 1H, J = 12.1 Hz, BnH), 4.73 (m, 2H, BnH), 4.83–4.89 (app t, 2H, J = 9.5, 10.5 Hz, BnH), 5.03 (d, 1H, J = 10.9 Hz, BnH), 5.32 (d, 1H, J = 3.5 Hz, H1), 7.17–7.38 (m, 20H, ArH). 13C NMR (CDCl3, 75 MHz): δ 30.7, 36.3, 42.5, 68.8, 69.7, 72.8, 73.4, 74.5, 75.1, 75.5, 78.2, 80.1, 82.1, 89.9 (C1), 127.5, 127.6, 127.7, 127.76, 127.8, 127.9, 128.0, 128.1, 128.3, 138.36, 138.1, 138.4, 138.42, 139.1. HRMS (ESI-TOF): calculated for C44H50O6 Na (M + Na) 697.3575, found 697.3507.
:
1) to afford the compound 9 in 85% β as colorless syrup.19b Rf = 0.36 (hexane/ethyl acetate, 4/1); [α]22D −24 (c 1.0, CHCl3); 1H NMR (CDCl3, 300 MHz): δ 1.33 (s, 6H, CH3), 1.52 (s, 3H, CH3), 1.55 (s, 3H, CH3), 3.45–3.50 (m, 2H), 3.59–3.69 (m, 2H), 3.72–3.78 (m, 2H), 4.11 (m, 1H, H5), 4.18 (dd, 1H, J = 3.3, 10.5 Hz, H6), 4.26 (bd, 1H, J = 7.9 Hz, H4), 4.33 (dd, 1H, J = 2.0, 4.5 Hz, H2), 4.46–4.65 (m, 5H, BnH, H′1, H3, H6), 4.71–4.84 (m, 4H, BnH), 4.97 (d, 1H, J = 10.9 Hz, BnH), 5.07 (d, 1H, J = 11.0 Hz, BnH), 5.58 (d, 1H, J = 4.9 Hz, H1), 7.14–7.44 (m, 20H, ArH). 13C NMR (CDCl3, 100 MHz): δ 24.5, 25.1, 26.1, 26.1, 67.4, 68.9, 69.8, 70.6, 70.9, 71.5, 73.6, 74.4, 74.9, 75.1, 75.7, 77.8, 81.7, 84.6, 96.5 (C′1), 104.5 (C1), 108.6 (CMe2), 109.4 (CMe2), 127.5, 127.6, 127.7, 127.8, 127.9, 128.0, 128.3, 128.4, 128.7, 138.2, 138.8. HRMS (ESI-TOF): calculated for C46H54O11Na (M + Na) 805.3558 found 805.3559.
O), 165.6 (C
O), 165.9 (C
O). HRMS (ESI-TOF): calculated for C62H60O14Na (M + Na) 1051.3881 found 1051.3880.
:
1) to afford the compound 14 in 88% β as white foam36 Rf = 0.52 (hexane/ethyl acetate, 3/1); 1H NMR (CDCl3, 300 MHz): δ 3.38–3.43 (m, 3H), 3.43 (s, 3H, OCH3), 3.51–3.68 (m, 4H), 3.77–4.00 (m, 5H), 4.29 (d, 1H, J = 11.8 Hz, BnH), 4.36–4.45 (m, 2H), 4.37 (d, 1H, J = 7.5 Hz, H′1), 4.57–4.76 (m, 6H, BnH, H1), 4.80–4.90 (m, 4H), 5.03 (d, 1H, J = 11.4 Hz, BnH), 5.10 (d, 1H, J = 11.7 Hz, BnH), 7.19–7.44 (m, 35H, ArH). 13C NMR (CDCl3, 75 MHz): δ 55.3, 68.1, 68.3, 70.1, 72.6, 73.2, 73.5, 73.7, 73.8, 74.8, 75.3, 75.5, 77.3, 79.0, 80.1, 80.3, 82.5, 98.5 (C′1), 102.9 (C1), 127.0, 127.3, 127.4, 127.5, 127.53, 127.6, 127.67, 127.7, 127.8, 127.9, 128.1, 128.16, 128.2, 128.3, 128.4, 138.2, 138.3, 138.6, 138.7, 139.0, 139.1, 139.5. HRMS (ESI-TOF): calculated for C62H66O11Na (M + Na) 1009.4501 found 1009.4503.
:
1) to afford the compound 16 in 89% β as colorless syrup. Rf = 0.35 (hexane/ethyl acetate, 4.5/1); 1H NMR (CDCl3, 300 MHz): δ 3.35 (s, 3H, OCH3), 3.36–3.43 (m, 2H), 3.49 (dd, 1H, J = 2.6, 9.7 Hz), 3.59–3.72 (m, 4H), 3.76–3.88 (m, 3H), 4.19–4.37 (m, 4H), 4.46 (d, 1H, J = 3.7 Hz, H1), 4.52 (d, 1H, J = 12.1 Hz, BnH), 4.61 (d, 1H, J = 11.4 Hz, BnH), 4.70 (bs, 2H, BnH), 4.74–4.82 (m, 3H, BnH, H′1), 4.94 (d, 1H, J = 11.6 Hz, BnH), 5.04 (d, 1H, J = 11.0 Hz, BnH), 5.51 (s, 1H, PhCH), 7.19–7.48 (m, 30H, ArH). 13C NMR (CDCl3, 125 MHz): δ 55.2, 63.2, 68.7, 70.2, 70.7, 73.3, 73.5, 73.6, 74.7, 75.0, 78.9, 79.5, 82.4, 98.2 (C′1), 103.90 (C1), 103.91 (PhCH) 127.4, 127.7, 127.8, 127.9, 128.0, 128.04, 128.13, 1228.26, 128.39, 128.42, 128.50, 128.55, 129.1, 129.8, 134.5, 136.6, 137.8, 138.4, 138.5, 138.6, 139.0. HRMS (ESI-TOF): calculated for C55H58O11Na (M + Na) 917.3878 found 917.3877.
:
1) to afford the compound 18 in 90% β as colorless syrup.38 Rf = 0.35 (hexane/ethyl acetate, 4.5/1); 1H NMR (CDCl3, 300 MHz): δ 3.45–3.47 (m, 6H, OCH3), 3.57–3.61 (m, 2H), 3.73–3.78 (m, 2H), 3.79–3.85 (m, 3H), 3.81 (d, 1H, J = 2.3 Hz), 4.36 (dd, 1H, J = 4.9, 10.4 Hz, H6), 4.42 (bs, 2H), 4.51 (d, 1H, J = 6.5 Hz, H′1), 4.62 (d, 1H, J = 11.6 Hz, BnH), 4.67–4.76 (m, 4H, BnH), 4.80 (d, 1H, J = 4.8 Hz, H1), 4.83 (d, 1H, J = 7.9 Hz, BnH), 4.94 (d, 1H, J = 10.8 Hz, BnH), 4.95 (d, 1H, J = 11.6 Hz, BnH), 5.56 (s, 1H, PhCH), 7.16–7.38 (m, 30H, ArH). 13C NMR (CDCl3, 75 MHz): δ 56.7, 65.6, 68.7, 68.9, 72.9, 73.4, 73.5, 73.7, 74.6, 74.9, 75.1, 79.3, 79.9, 81.3, 81.5, 82.5, 101.1 (PhCH), 102.8 (C′1), 103.4 (C1), 126.0, 127.3, 127.5, 127.6, 127.7, 127.8, 128.0, 128.1, 128.2, 128.23, 128.3, 128.37, 128.4, 128.9, 137.4, 137.9, 138.4, 138.5, 138.7, 138.9. HRMS (ESI-TOF): calculated for C55H58O11Na (M + Na) 917.3878, found 917.3877.
:
1 to afford 26 in 90% as white solid.22b Rf = 0.29 (25% ethyl acetate in hexane). [α]26D +28.2 (c 1.0, CHCl3); 1H (300 MHz, CDCl3): δ 1.72 (s, 3H, COCH3), 1.92 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 3.41 (s, 3H, OCH3), 3.78–3.96 (m, 6H, H3, H4, H5, H′5, H6, H6), 4.34 (dd, 1H, J = 3.9, 9.9 Hz, H′6), 4.45 (app t, 1H, J = 9.2, 9.6 Hz, H′6), 5.01 (d, 1H, J = 5.9 Hz, H1), 5.07–5.18 (m, 2H, H′1, H′4), 5.22 (dd, 1H, J = 3.7, 9.8 Hz, H′3), 5.34–5.36 (m, 2H, H2, H′2), 5.60 (s, 1H, CHPh), 7.27–7.60 (m, 8H, ArH), 8.08 (d, 2H, J = 6.5 Hz, ArH). 13C NMR (75 MHz, CDCl3): δ 20.4, 20.6, 20.7, 55.5, 61.8, 62.1, 65.4, 68.3, 68.8, 69.0, 69.1, 71.7, 72.7, 77.4, 82.2, 97.8, 101.3 (PhCH), 126.0, 128.1, 128.5, 128.9, 129.4, 129.8, 133.5, 136.8, 165.5 (C
O), 169.4 (C
O), 169.6 (C
O), 169.7 (C
O), 170.6 (C
O). HRMS (ESI-TOF): calculated for C35H40O16Na [M + Na]+ 716.2316, found 716.2317.
:
1) to afford 28 in 89% as white solid.22b Rf = 0.38 (hexane/ethyl acetate, 4/1); mp 162–164 °C (from ethyl acetate–hexane); [α]25D +44 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ 0.75 (d, 3H, J = 6.2 Hz, CH3), 1.89 (s, 3H, COCH3), 1.91 (s, 3H, COCH3), 1.93 (s, 3H, COCH3), 3.38 (s, 3H, OCH3), 3.72 (t, 1H, J = 9.4 Hz), 3.82 (t, 1H, J = 10.2 Hz), 3.94 (dt, 1H, J = 4.6, 9.9 Hz, H5), 4.16 (m, 1H, H′5), 4.34 (dd, 1H, J = 4.5, 10.0 Hz, H6), 4.42 (app t, 1H, J = 9.3, 11.6 Hz, H6), 4.89 (t, 1H, J = 10.0 Hz, H′4), 5.00 (s, 1H, H′1), 5.04–5.09 (m, 3H, H1, H2, H′2), 5.22 (dd, 1H, J = 3.5, 10.0 Hz, H′3), 5.59 (s, 1H, CHPh), 7.29–7.59 (m, 8H, ArH), 7.98–8.01 (m, 2H, ArH). 13C NMR (CDCl3, 75 MHz): δ 16.6, 20.4, 20.5, 20.6, 29.6, 55.4, 62.6, 66.2, 68.8, 68.9, 69.4, 70.9, 73.2, 74.7, 79.5, 97.7, 98.0, 101.9 (PhCH) 126.3, 128.0, 128.3, 129.1, 129.8, 133.3, 137.1, 165.6 (C
O), 169.2 (C
O), 169.8 (C
O). HRMS (ESI-TOF): calculated for C33H38O14Na (M + Na) 658.2262 found 658.2261.
:
1) to afford 31 (91%) as a white foam.22d Rf = 0.28 (25% ethyl acetate in hexane). [α]26D +28.2 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3): δ 2.01 (s, 3H, COCH3), 3.35 (s, 3H, OCH3), 3.43 (d, 1H, J = 10.8 Hz), 3.63 (dd, 1H, J = 3.0, 10.8 Hz), 3.70–3.77 (m, 5H), 3.84–3.85 (m, 3H), 4.16 (t, 1H, J = 9.0 Hz), 4.35 (d, 1H, J = 12.0 Hz), 4.41 (brs, 1H), 4.43 (brs, 1H), 4.53–4.58 (m, 3H), 4.60–4.65 (m, 4H), 4.67 (d, 1H, J = 10.8 Hz), 4.76 (s, 1H, H1), 4.80 (d, 1H, J = 10.8 Hz), 5.42 (brs, 1H, H′1), 5.47 (brs, 1H), 7.13–7.34 (m, 30H, ArH). 13C NMR (150 MHz, CDCl3): δ 21.0, 54.9, 68.5, 68.6, 69.9, 71.4, 71.1, 71.7, 72.3, 72.5, 73.2, 73.4, 73.9, 74.0, 75.0, 78.4, 80.1, 98.7 (C1), 99.4 (C′1), 127.3, 127.4, 127.45, 127.5, 127.57, 127.6, 127.7, 127.8, 127.9, 128.0, 128.2, 128.27, 128.3, 137.9, 138.1, 138.2, 138.3, 138.4, 138.5, 169.9 (C
O); HRMS (ESI-TOF) : calculated for C57H62O12Na [M + Na]+ 961.4139 found 961.4131.
:
1) to afford 33 (91%) as a white foam. Rf = 0.21 (25% ethyl acetate in hexane). [α]26D +59.5 (c 1.06, CHCl3); 1H NMR (600 MHz, CDCl3): δ 3.25 (s, 3H, OCH3), 3.39 (d, 1H, J = 9.6 Hz), 3.60–3.64 (m, 2H), 3.76 (t, 1H, J = 2.4 Hz), 3.90 (d, 1H, J = 3.0 Hz), 3.94 (t, 1H, J = 6.6 Hz), 4.26 (dd, 1H, J = 8.0, 12.0 Hz), 4.37 (apparent t, 2H, J = 9.0, 9.6 Hz), 4.40 (apparent t, 2H, J = 4.8, 6.0 Hz), 4.61 (d, 1H, J = 12.0 Hz), 4.67–4.73 (m, 3H, H1), 4.92 (d, 1H, J = 12.0 Hz), 4.99 (d, 1H, J = 8.4 Hz, H′1), 5.40 (dd, 1H, J = 3.6, 10.8 Hz), 5.72 (dd, 1H, J = 8.4, 10.2 Hz), 5.87 (d, 1H, J = 3.6 Hz), 7.17–7.57 (m, 27H, ArH), 7.76 (d, 2H, J = 7.2 Hz, ArH), 7.89 (d, 2H, J = 7.8 Hz, ArH), 7.94 (d, 2H, J = 7.8 Hz, ArH), 7.97 (d, 2H, J = 7.2 Hz, ArH). 13C NMR (150 MHz, CDCl3): δ 54.9, 61.8, 68.8, 70.7, 71.2, 72.1, 72.7, 73.0, 73.5, 75.6, 78.5, 99.5 (C1) 101.2 (C′1), 127.0, 127.4, 127.6, 127.9, 128.0, 128.4, 128.5, 128.6, 128.7, 129.0, 129.3, 129.4, 129.7, 129.9, 130.0, 133.26, 133.30, 133.4, 133.5, 138.6, 139.3, 165.3 (C
O), 165.6 (C
O), 165.7 (C
O), 166.0 (C
O). HRMS (ESI-TOF): calculated for C62H58O15Na [M + Na]+ 1065.3673, found 1065.3665.
:
1) to get pure product 35 in 88% yield. It was crystallized from PE/EtOAc; mp 232–234 °C. [α]25D +38.8 (c 1.39, CHCl3). 1H NMR (CDCl3, 300 MHz): δ 3.12 (s, 3H, OCH3), 3.66–3.83 (m, 3H), 3.90 (app t, 1H, J = 9.4, 9.7 Hz), 4.08 (bd, 1H, J = 10.9 Hz), 4.21 (app t, 1H, J = 8.0, 9.3 Hz, H6), 4.42 (dd, 1H, J = 4.6, 10.2 Hz, H6), 4.91 (d, 1H, J = 4.1 Hz, H1), 4.93 (d, 1H, J = 7.3 Hz, H′1), 5.11 (dd, 1H, J = 3.3, 10.2 Hz, H2), 5.33 (ABq, 1H, J = 9.7 Hz, H3), 5.48–5.58 (m, 2H, CHPh, H′2), 5.81 (t, 1H, J = 9.5 Hz, H′3), 6.08 (t, 1H, J = 9.8 Hz, H4), 7.27–7.50 (m, 20H, ArH), 7.90 (d, 2H, J = 8.5 Hz, ArH), 7.89–7.99 (m, 8H, ArH). 13C NMR (75 MHz, CDCl3): δ 55.0, 66.6, 68.5, 68.6, 69.6, 70.3, 71.9, 72.0, 72.4, 78.7, 96.4 (C′1), 101.4 (PhCH), 102.0 (C1) 126.1, 128.19, 128.16, 128.26, 128.29, 128.33, 128.4, 129.0, 129.3, 129.6, 129.77, 129.84, 133.0, 133.1, 133.2, 133.4, 136.7, 165.3 (C
O), 165.4 (C
O), 165.6 (C
O), 165.7 (C
O). HRMS m/z calculated for (C55H48O16Na+) [M + Na]+ 987.2840, found: 987.2841.
:
1) to afford 37 (90%) as a white solid. Rf 0.30 (25% EtOAc in hexane); mp 185–186 °C (from PE–ethyl acetate); [α]26D +29.6 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ 2.07 (s, 3H, COCH3), 3.42 (m, 1H), 3.46 (s, 3H, OCH3), 3.68 (dd, 1H, J = 6.7, 10.8 Hz), 3.71–3.77 (m, 3H), 4.05 (dd, 1H J = 1.5, 10.8 Hz), 4.25 (m, 1H), 4.31 (dd, 1H, J = 4.9, 10.5 Hz), 4.54 (d, 1H, J = 7.9 Hz, H′1), 4.69 (d, 1H, J = 12.1 Hz, BnH), 4.88 (d, 1H, J = 12.1 Hz, BnH), 5.08 (dt, 1H, J = 2.4, 7.6 Hz, H′1), 5.23–5.27 (m, 2H, H1, H2), 5.45 (t, 1H, J = 9.8 Hz, H3), 5.55 (s, 1H, PhCH), 6.15 (t, 1H, J = 9.3 Hz, H4), 7.26–7.31 (m, 7H, ArH), 7.35–7.42 (m, 8H, ArH), 7.49–7.54 (m, 4H, ArH), 7.85–7.88 (m, 2H, ArH), 7.94–7.99 (m, 4H, ArH). 13C NMR (75 MHz, CDCl3): δ 20.9, 55.4, 66.2, 68.3, 68.5, 69.4, 70.5, 72.0, 72.6, 74.1, 78.4, 81.4, 96.7, 101.2 (C1), (PhCH), 101.8 (C1), 126.0, 127.6, 127.8, 128.2, 128.3, 128.40, 128.43, 128.87, 128.99, 129.03, 129.6, 129.8, 129.9, 133.0, 133.3, 133.5, 137.1, 138.2, 165.3 (C
O), 165.7 (C
O), 165.8 (C
O), 169.4 (C
O); HRMS (ESI-TOF) calculated for C50H48O15Na [M + Na]+ 911.2891, found 911.2889.
:
1) to afford 39 (89%) as a white foam. Rf 0.30 (20% EtOAc in hexane); 1H NMR (CDCl3, 300 MHz): δ 1.33 (s, 4H), 1.69 (s, 8H), 3.43 (d, 2H, J = 3.43 Hz), 3.54–3.66 (m, 5H), 3.75–3.87 (m, 4H), 3.94–4.01 (m, 2H), 4.05–4.19 (m, 3H), 4.36 (m, 1H), 4.41–4.54 (m, 2H), 4.91 (d, 1H, J = 8.3 Hz), 4.59 (m, 1H), 4.66–4.84 (m, 3H), 4.91 (d, 1H, J = 8.3 Hz, H′′1), 5.38 (m, 1H), 5.44–5.53 (m, 2H), 5.87 (t, 1H, J = 9.5 Hz), 7.15–7.49 (m, 29H, ArH), 7.81 (d, 2H, J = 7.7 Hz, ArH), 7.92 (d, 2H, J = 7.4 Hz, ArH), 7.97 (d, 2H, J = 7.5 Hz, ArH). 13C NMR (CDCl3, 75 MHz): δ 24.1, 24.8, 25.7, 25.9, 67.4, 68.6, 68.7, 68.8, 70.3, 70.4, 70.5, 70.8, 71.8, 73.2, 73.5, 74.0, 74.7, 74.8, 74.9, 75.6, 77.7, 82.1, 84.6, 96.1 (C1), 101.3 (C′′1), 103.9 (C′1), 108.3 (CMe2), 109.2 (CMe2), 127.5, 127.6, 127.7, 127.8, 127.91, 127.97, 128.15, 128.19, 128.24, 128.3, 128.4, 128.5, 128.7, 128.9, 129.7, 129.8, 130.0, 132.9, 133.1, 133.3, 133.4, 138.0, 138.2, 138.7, 165.2 (C
O), 165.4 (C
O), 165.8 (C
O); HRMS (ESI): calculated for C73H76O19Na (M + Na) 1279.4879 found 1279.4870.
:
2) to afford 42 (83%) as a white foam. Rf 0.31 (60% EtOAc in hexane). [α]24D +24.6 (c 1.0, CHCl3); lit.22d [α]20D +23.9 (c 0.8, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.80 (s, 3H, COCH3), 1.84 (s, 3H, COCH3), 1.97 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 2.12 (s, 3H, COCH3), 3.06 (s, 3H, OCH3), 3.17–3.19 (m, 2H), 3.40 (app t, 1H, J = 9.0, 10.0 Hz), 3.52–3.59 (m, 2H), 3.66–3.68 (m, 2H), 3.76 (app t, 1H, J = 8.5, 9.5 Hz), 3.84 (dd, 1H, J = 2.5, 12.5 Hz), 4.08 (dd, 1H, J = 4.0, 12.5 Hz), 4.11–4.20 (m, 4H), 4.34 (dd, 1H, J = 5.0, 12.5 Hz), 4.41 and 4.53 (d, each 1H, J = 12.0 Hz, BnH), 4.82 and 4.90 (d, J = 12.0 Hz, each 1H, BnH), 5.05–5.12 (m, 3H), 5.47 (d, 1H, J = 8.5 Hz), 5.52 (dd, 1H, J = 9.5, 10.5 Hz), 5.69 (dd, 1H, J = 9.5, 10.5 Hz), 7.15–7.16 (m, 2H, ArH), 7.21–7.26 (m, 4H, ArH), 7.32–7.33 (m, 4H, ArH), 7.65–7.67 (m, 2H, ArH), 7.75–7.79 (m, 4H, ArH), 7.87–7.88 (m, 2H, ArH). 13C NMR (125 MHz, CDCl3): δ 20.4, 20.5, 20.7, 20.8, 20.9, 54.58, 55.0, 55.4, 61.8, 62.2, 68.7, 68.8, 69.2, 69.3, 70.8, 70.85, 71.8, 73.3, 74.5, 77.3, 79.5, 79.8, 97.5, 97.6, 99.0, 123.5, 123.9, 126.8, 127.2, 127.9, 128.0, 128.3, 128.4, 131.4, 131.7, 134.2, 134.7, 138.1, 139.5, 169.5 (C
O), 170.2 (C
O), 170.8 (C
O), 170.9 (C
O). HRMS (ESI-TOF) calcd for C50H48O15Na [M + Na]+ 911.2891, found 911.2889.
:
1 to afford 43 in 81% as white foam. 1H NMR (300 MHz, CDCl3): δ 0.79 (d, 3H, J = 6.2 Hz, CH3), 1.20 (d, 3H, J = 6.2 Hz, CH3), 1.97 (s, 3H, COCH3), 1.98 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 2.12 (s, 3H, COCH3), 3.39 (s, 3H, OCH3), 3.60 (dd, 1H, J = 3.6, 9.4 Hz), 3.65–3.78 (m, 4H), 3.83–3.95 (m, 3H), 4.00 (m, 1H), 4.57 (d, 1H, J = 3.5 Hz, H1), 4.59 (d, 1H, J = 12.0 Hz, BnH), 4.62 (d, 1H, J = 12.0 Hz, BnH), 4.72 (app t, 1H, J = 5.1, 5.7 Hz), 4.74 (d, 1H, J = 11.9 Hz, BnH), 4.80 (d, 1H, J = 1.5 Hz, H′1/H′′1), 4.88 (d, 1H, J = 1.5 Hz, H′′1/H′1), 4.97 (d, 1H, J = 10.1 Hz, BnH), 4.99–5.0 (m, 1H), 5.08 (d, 1H, J = 11.2 Hz, BnH), 5.13 (dd, 1H, J = 1.7, 3.5 Hz), 5.22 (dd, 1H, J = 3.5, 10.2 Hz), 5.27 (dd, 1H, J = 3.6, 6.5 Hz), 7.25–7.39 (m, 10H, ArH).
:
1) to afford the compound 45 (44.86 mg) in 97% β as white foam.40 Rf = 0.42 (hexane/ethyl acetate, 4/1); 1H (300 MHz, CDCl3): δ 3.72–3.86 (m, 6H), 4.52–4.62 (m, 3H, BnH), 4.82–4.89 (m, 3H, BnH), 4.97 (d, 1H, J = 10.8 Hz, BnH), 5.11 (d, 1H, J = 10.8 Hz, BnH), 5.16 (d, 1H, J = 6.7 Hz, H1), 7.23–7.45 (m, 24H, ArH), 7.66 (d, 1H, J = 7.7 Hz, ArH), 7.76–7.80 (m, 2H, ArH).
:
0.5) to afford the compound 47 in 97% β as white solid.41 Rf = 0.54 (hexane/ethyl acetate, 9/1); 1H NMR (CDCl3, 500 MHz): δ 3.60 (m, 1H), 3.68–3.76 (m, 4H), 3.80 (s, 3H, OCH3), 3.83 (dd, 1H, J = 1.0, 10.0 Hz), 4.55–4.64 (m, 3H, BnH, H1), 4.84–4.93 (m, 4H, BnH), 4.98 (d, 1H, J = 11.0 Hz, BnH), 5.08 (d, 1H, J = 11.0 Hz, BnH), 6.84 (d, 2H, J = 9.0 Hz, ArH), 7.06 (d, 2H, J = 12.5 Hz, ArH), 7.22 (d, 2H, J = 10.0 Hz, ArH), 7.27–7.38 (m, 18H, ArH). 13C NMR (CDCl3, 75 MHz): δ 55.8, 69.1, 73.6, 75.1, 75.2, 75.9, 76.7, 77.9, 82.2, 84.8, 102.9 (C1) 114.7, 118.6, 127.7, 127.7, 127.8, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 138.2, 138.3, 138.4, 138.7, 151.7, 155.4. HRMS (ESI-TOF): calculated for C41H42O7 Na (M + Na) 669.2823 found 669.2841.
:
0.5) to afford the compound 49 in 90% β as white solid.40 Rf = 0.52 (hexane/ethyl acetate, 9/1); [α]27D +96.4 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 2.39 (s, 6H, 2 × CH3), 3.32 (m, 1H, H5), 3.65–3.77 (m, 5H), 4.46 (d, 1H, J = 12.4 Hz, BnH), 4.54 (d, 1H, J = 12.0 Hz, BnH), 4.62 (d, 1H, J = 10.8 Hz, BnH), 4.79–4.89 (m, 4H, BnH, H1), 5.01 (d, 1H, J = 10.8 Hz, BnH), 5.16 (d, 1H, J = 10.8 Hz, BnH), 6.98–7.04 (m, 3H, ArH), 7.20 (d, 1H, J = 1.2 Hz, ArH), 7.21 (d, 1H, J = 2.0 Hz, ArH), 7.25–7.33 (m, 16H, ArH), 7.38–7.40 (m, 2H, ArH). 13C NMR (CDCl3, 125 MHz): δ 17.3, 69.1, 73.6, 75.10, 75.17, 75.4, 75.8, 78.0, 83.0, 84.9, 104.3 (C1) 124.6, 127.5, 127.6, 127.7, 127.8, 128.1, 128.2, 128.3, 128.4, 128.5, 128.9, 132.0, 138.3, 138.4, 138.8, 153.4. HRMS (ESI-TOF): calculated for C42H44O6Na (M + Na) 667.3729, found 667.3731.
:
0.5) to afford the compound 51 in 92% β as white solid.41 Rf = 0.54 (hexane/ethyl acetate, 9/1); 1H NMR (CDCl3, 500 MHz): 3.59–3.79 (m, 6H), 4.52 (d, 1H, J = 12.5 Hz, BnH), 4.56–4.60 (m, 2H, BnH), 4.82–4.87 (m, 3H, BnH), 4.94–4.98 (m, 2H, BnH, H1), 5.00 (d, 1H, J = 11.0 Hz, BnH), 6.95–6.97 (d, 2H, J = 8.5 Hz, ArH), 7.19–7.39 (m, 22H, ArH). 13C NMR (CDCl3, 75 MHz): δ 68.8, 73.5, 75.1, 75.3, 75.8, 77.7, 81.9, 84.7, 101.7 (C1) 127.8, 127.9, 128.0, 128.2, 128.4, 128.5, 132.4, 137.9, 138.1, 138.2, 138.5, 156.5.
:
1) to afford the compound 52 in 97% β as white foam.40 Rf = 0.42 (hexane/ethyl acetate, 4/1); 1H (300 MHz, CDCl3): δ 3.60–3.71 (m, 3H), 3.77 (t, 1H, J = 5.9 Hz), 3.98 (d, 1H, J = 2.4 Hz), 4.19 (app t, 1H, J = 8.0 Hz), 4.45 (ABq, 2H, J = 11.6 Hz, BnH), 4.66 (d, 1H, J = 11.6 Hz, BnH), 4.76 (d, 1H, J = 11.9 Hz, BnH), 4.81 (d, 1H, J = 11.9 Hz, BnH), 4.89 (d, 1H, J = 11.8 Hz, BnH), 4.98–5.06 (app t, 2H, J = 11.3, 13.2 Hz, BnH), 5.14 (d, 1H, J = 7.6 Hz, H1), 7.26–7.37 (m, 22H, ArH), 7.42 (d, 2H, J = 2.4 Hz, ArH), 7.64 (d, 1H, J = 7.9 Hz, ArH), 7.33–7.79 (m, 2H, ArH).
:
1) to afford compound 54 in 95% β as white foam.40 Rf = 0.62 (hexane/ethyl acetate, 4/1); 1H (300 MHz, CDCl3): δ 3.61–3.69 (m, 2H), 3.71–3.78 (m, 2H), 4.00 (d, 1H, J = 2.3 Hz), 4.32 (app t, 1H, J = 7.8, 9.4 Hz), 4.40 (d, 1H, J = 11.6 Hz, BnH), 4.47 (d, 1H, J = 11.7 Hz, BnH), 4.69 (d, 1H, J = 11.6 Hz, BnH), 4.79 (s, 2H, BnH), 4.97 (d, 1H, J = 10.6 Hz, BnH), 5.02 (d, 1H, J = 11.6 Hz, BnH), 5.12 (d, 1H, J = 10.6 Hz, BnH), 5.19 (d, 1H, J = 7.7 Hz, H1), 7.13 (d, 1H, J = 7.6 Hz, ArH), 7.23–7.41 (m, 22H, ArH), 7.46 (d, 1H, J = 8.4 Hz, ArH), 7.52 (d, 1H, J = 8.2 Hz, ArH), 7.80 (d, 1H, J = 7.7 Hz, ArH), 8.32 (d, 1H, J = 8.1 Hz, ArH).
:
1) to afford the compound 56 in 94% β as white solid. Rf = 0.62 (hexane/ethyl acetate, 4/1); [α]25D −20.84 (c 1.9, CHCl3); 1H (300 MHz, CDCl3): δ 2.28 (s, 3H, CH3), 3.59–3.67 (m, 4H), 3.94 (bd, 1H, J = 2.6 Hz), 4.09 (dd, 1H, J = 7.8, 9.5 Hz), 4.37–4.48 (2d, 2H, J = 11.0 Hz, BnH), 4.63 (d, 1H, J = 11.6 Hz, BnH), 4.71–4.80 (2d, 2H, J = 11.0 Hz, BnH), 4.85 (d, 1H, J = 10.9 Hz, BnH), 4.91 (d, 1H, J = 7.7 Hz, H1), 4.96 (d, 1H, J = 10.8 Hz, BnH), 4.98 (d, 1H, J = 11.6 Hz, BnH), 6.83–7.36 (m, 23H, ArH). 13C NMR (CDCl3, 125 MHz): δ 20.4, 69.1, 73.3, 73.5, 73.8, 74.1, 74.7, 75.6, 79.3, 82.2, 102.3 (C1), 115.9, 119.7, 127.72, 127.78, 127.8, 127.9, 127.98, 128.3, 128.4, 128.5, 128.6, 129.7, 137.1, 137.9, 138.5, 138.6, 156.1. HRMS (ESI): calculated for C41H41ClO6Na (M + Na) 664.2592, found 664.2491.
:
0.5) to afford the compound 57 in 91% β as white solid.41 Rf = 0.52 (hexane/ethyl acetate, 9/1); 1H NMR (CDCl3, 300 MHz): δ 2.35 (s, 6H, 2 × CH3), 3.41–3.52 (m, 2H), 3.57–3.65 (m, 2H), 3.93 (bd, 1H, J = 2.5 Hz), 4.11 (dd, 1H, J = 7.7, 9.7 Hz), 4.35 (bs, 2H, BnH), 4.64 (d, 1H, J = 11.7 Hz, BnH), 4.72–4.82 (m, 3H, BnH, H1), 4.89 (d, 1H, J = 10.9 Hz, BnH), 5.00 (d, 1H, J = 11.7 Hz, BnH), 5.10 (d, 1H, J = 10.9 Hz, BnH), 6.93–7.02 (m, 2H, ArH), 7.16–7.19 (m, 2H, ArH), 7.26–7.29 (m, 19H, ArH).
:
1 to give 60 in 88% as white foam; [α]25D +60.05 (c 1.28, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 1.77–1.88 (m, 2H, CH2), 3.15–3.27 (m, 2H, NCH2), 3.67 (m, 1H, OCH), 4.03 (m, 1H, H5), 4.32 (t, 1H, J = 6.5 Hz, OCH), 4.42 (dd, 1H, J = 6.8, 11.8 Hz, H6), 4.67 (dd, 1H, J = 6.5, 11.5 Hz, H6), 4.81 (d, 1H, J = 7.5 Hz, H1), 5.00 (m, 1H, NH), 5.05 (s, 2H, BnH), 5.62 (dd, 1H, J = 3.8, 10.3 Hz, H3), 5.78 (dd, 1H, J = 8.3, 10.3 Hz, H2), 5.99 (d, 1H, J = 3.5 Hz, H4), 7.21–7.26 (m, 2H, ArH), 7.29 (m, 1H, ArH), 7.33–7.36 (m, 6H, ArH), 7.41–7.44 (m, 3H, ArH), 7.46–7.51 (m, 3H, ArH), 7.55 (t, 1H, J = 7.5 Hz, ArH), 7.62 (t, 1H, J = 7.5 Hz, ArH), 7.77–7.79 (d, 2H, J = 8.0 Hz, ArH), 7.94–7.95 (d, 2H, J = 8.0 Hz, ArH), 8.00–8.02 (m, 2H, ArH), 8.08–8.09 (d, 2H, J = 8.0 Hz, ArH); 13C NMR (125 MHz, CDCl3): δ 29.7, 38.3, 62.2, 66.6, 68.3, 70.0, 71.6, 71.7, 101.8 (C1), 128.1, 128.4, 128.6, 128.8, 128.9, 129.2, 129.4, 129.6, 129.8, 129.9, 130.2, 133.4, 133.5, 133.7, 156.6 (C
O), 165.7 (C
O), 166.2 (C
O); HRMS m/z calcd for C45H41NO12Na+ calcd: 810.2527, found: 810.2526.
:
1) to get pure product (62) as colourless syrup in 92% yield. [α]29D −2.57 (c 7.0, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.68–1.76 (m, 2H, CH2), 1.97 (s, 3H, COCH3), 3.23 (m, 1H, NCH), 3.33–3.37 (m, 3H), 3.38–3.43 (m, 2H), 3.46 (m, 1H), 3.55–3.59 (m, 2H), 3.69 (d, 1H, J = 10.0 Hz), 3.74–3.77 (m, 2H), 3.85 (m, 1H), 3.9 (d, 1H, J = 2.5 Hz), 3.95 (t, 1H, J = 9.0 Hz), 4.23 (d, 1H, J = 12.0 Hz), 4.29–4.34 (app t, 2H, J = 10.5, 11.5 Hz), 4.36–4.38 (dd, 2H, J = 1.5, 9.0 Hz), 4.48 (d, 1H, J = 12.0 Hz, BnH), 4.54 (d, 1H, J = 11.0 Hz, BnH), 4.58 (d, 1H, J = 11.0 Hz, BnH), 4.68 (d, 1H, J = 12.0 Hz, BnH), 4.72 (d, 1H, J = 12.0 Hz, BnH), 4.75 (d, 1H, J = 11.0 Hz, BnH), 4.82 (d, 1H, J = 11.0 Hz, BnH), 4.94–4.98 (m, 3H, H1, H′1, H2), 5.08 (bs, 2H, BnH), 5.29 (bs, 1H, NH), 7.19–7.36 (m, 35H, ArH). 13C NMR (75 MHz, CDCl3): δ 20.9, 29.5, 38.2, 66.5, 66.7, 68.1, 68.3, 72.5, 72.6, 73.1, 73.5, 73.7, 74.3, 74.7, 75.3, 79.9, 80.8, 82.5, 100.8 (C1), 102.9 (C′1), 127.2, 127.4, 127.5, 127.57, 127.62, 127.7, 127.9, 128.0, 128.1, 128.2, 128.3, 128.3, 128.4, 128.5, 136.9, 138.1, 128.2, 138.5, 138.8, 139.0, 139.1, 156.6 (C
O), 169.6 (C
O). HRMS (TOF): calc. for (M + Na)+ C67H73NO14Na 1138.4929, found 1138.4932.
:
1) to get pure product (64) as colourless syrup in 94% yield. 1H NMR (CDCl3, 300 MHz): δ 1.49–1.61 (m, 6H), 1.66–1.70 (m, 3H), 1.83–1.87 (m, 3H), 2.04 (s, 3H), 4.22 (m, 1H, H5), 4.52–4.60 (m, 2H, H6, H6), 5.16 (d, 1H, J = 7.9 Hz, H1), 5.49–5.62 (m, 2H, H2, H4), 5.95 (t, 1H, J = 9.6 Hz, H3), 7.28–7.55 (m, 12H, ArH), 7.85–8.06 (m, 8H, ArH).
:
1) to get pure product (65) as colourless syrup in 89% yield. 1H NMR (CDCl3, 300 MHz): δ 1.49–1.56 (m, 6H), 1.64–1.71 (m, 3H), 1.84–1.87 (m, 3H), 2.04 (s, 3H), 4.34 (m, 1H, H5), 4.46 (dd, 1H, J = 5.9, 11.0 Hz, H6), 4.59 (dd, 1H, J = 3.1, 10.8 Hz, H6), 5.09 (d, 1H, J = 7.9 Hz, H1), 5.60 (dd, 1H, J = 3.1, 10.2 Hz, H3), 5.78 (app t, 1H, J = 8.2, 9.8 Hz, H2), 5.97 (bs, 1H, H4), 7.23–7.59 (m, 12H, ArH), 7.78–7.80 (d, 2H, J = 7.7 Hz, ArH), 7.95–7.98 (d, 2H, J = 7.5 Hz, ArH), 8.03–8.06 (d, 2H, J = 7.6 Hz, ArH), 8.10–8.13 (d, 2H, J = 7.6 Hz, ArH). 13C NMR (CDCl3, 75 MHz): δ 30.6, 36.1, 42.4, 62.5, 68.4, 69.9, 71.2, 72.2, 75.8, 94.6 (C1) 128.3, 128.37, 128.42, 128.6, 128.9, 129.1, 129.67, 129.72, 129.8, 130.2, 133.1, 133.2, 133.5, 165.6, 165.8, 166.1.
:
1) to get pure product (67) as colourless syrup in 91% yield. 1H NMR (CDCl3, 500 MHz): δ 1.92 (s, 6H, COCH3), 1.95 (s, 3H, COCH3), 1.97 (s, 3H, COCH3), 3.28 (m, 1H), 3.34 (s, 3H, OCH3), 3.44 (dd, 1H, J = 4.0, 9.0 Hz), 3.56–3.60 (m, 2H), 3.73 (dd, 1H, J = 3.5, 11.0 Hz), 3.81–3.86 (m, 3H), 4.11 (dd, 1H, J = 4.0, 12.0 Hz), 4.40 (d, 1H, J = 12.0 Hz, BnH), 4.48 (d, 1H, J = 8.0 Hz, H′1), 4.55 (d, 1H, J = 3.5 Hz, H1), 4.56 (d, 1H, J = 12.5 Hz, BnH), 4.71 (app t, 3H, J = 11.0, 12.0 Hz, BnH), 4.86 (app t, 1H, J = 8.0, 9.0 Hz, H′2), 4.91–5.00 (m, 3H, BnH, H′3, H′4), 7.21–7.27 (m, 8H, ArH), 7.33–7.39 (m, 7H, ArH). 13C NMR (CDCl3, 75 MHz): δ 20.6 (COCH3), 20.7 (COCH3), 55.4, 67.6, 68.1, 69.7, 71.5, 71.9, 73.2, 73.5, 73.7, 75.2, 78.9, 79.9, 98.4 (C1), 100.0 (C′1), 127.2, 127.4, 127.8, 128.1, 128.2, 128.22, 128.4, 128.7, 137.7, 138.3, 139.4, 169.1 (C
O), 169.4 (C
O), 170.2 (C
O), 170.7 (C
O).
:
1) to afford the title compound 70 as colorless syrup (91%); 1H NMR (CDCl3, 300 MHz): δ 1.20 (d, 3H, J = 5.7 Hz), 1.37 (d, 3H, J = 6.0 Hz, CH3), 3.81 (s, 3H, OCH3), 4.18–4.28 (m, 2H), 4.72 (bd, 1H, J = 9.6 Hz), 5.34 (bs, 2H), 5.54 (app t, 1H, J = 9.6, 10.0 Hz), 5.63–5.67 (m, 2H), 5.71–5.74 (m, 2H), 6.88–6.90 (d, 2H, J = 7.2 Hz, ArH), 7.09–7.11 (m, 2H, ArH), 7.20–7.25 (t, 1H, J = 7.2 Hz, ArH), 7.28–7.37 (m, 3H, ArH), 7.39–7.51 (m, 7H, ArH), 7.61–7.63 (m, 3H, ArH), 7.68 (d, 1H, J = 6.2 Hz, ArH), 7.72–7.78 (app t, 4H, J = 8.1, 8.5 Hz, ArH), 7.94–7.96 (d, 2H, J = 6.2 Hz, ArH), 8.15–8.18 (d, 2H, J = 7.8 Hz, ArH), 8.28–8.31 (d, 2H, J = 7.8 Hz, ArH).
:
1) to afford the title compound 73 as colorless syrup (90%); [α]25D +10.2 (c 1.5, CHCl3); 1H NMR (300 MHz, CDCl3): δ 2.14 (s, 3H, COCH3), 3.23 (s, 3H, OCH3), 3.53 (d, 1H, J = 10.5 Hz) 3.65–3.84 (m, 9H), 3.87–3.93 (m, 4H), 3.95–3.99 (m, 2H), 4.11 (bs, 1H), 4.32 (d, 1H, J = 12.1 Hz, BnH), 4.41–4.47 (m, 2H), 4.51–4.67 (m, 11H), 4.70 (d, 1H, J = 3.3 Hz), 4.81–4.87 (m, 4H), 5.06 (brs, 1H), 5.21 (brs, 1H), 5.55 (bs, 1H, H′′2), 7.15–7.36 (m, 45H, ArH); 13C NMR (75 MHz, CDCl3): δ 21.2 (COCH3), 54.7 (OCH3), 68.8, 69.6, 71.7, 71.9, 72.1, 72.2, 73.3, 73.4, 74.3, 74.9, 75.0, 75.1, 78.1, 79.3, 79.5, 99.4, 99.8, 100.6, 127.4, 127.5, 127.6, 127.7, 127.8, 127.9, 128.0, 128.16, 128.23, 128.3, 128.4, 138.1, 138.2, 138.4, 138.5, 138.6, 170.1 (C
O).
:
1) to afford the compound 75 in 85% β only as white solid,33c Rf 0.33 (20% EA in hexane); mp 146–148 °C (from MeOH), lit.33c mp 147–148 °C, [α]25D +11.8 (c 1.05, CHCl3); lit.33c [α]24D +10.4 (c 1.08, CHCl3). 1H NMR (CDCl3, 300 MHz): δ 3.37–3.52 (m, 4H), 3.57–3.92 (m, 7H), 4.08 (appatent t, 1H, J = 9.2, 9.5 Hz), 4.43 (bs, 2H), 4.48–4.68 (m, 5H), 4.72–4.86 (m, 7H), 4.93 (d, 1H, J = 10.8 Hz, BnH), 5.17 (d, 1H, J = 11.1 Hz, BnH), 7.19–7.34 (m, 38H, ArH), 7.58–7.61 (m, 2H, ArH). 13C NMR (CDCl3, 75 MHz): δ 68.3, 68.9, 73.2, 73.3, 74.8, 75.0, 75.5, 75.7, 76.4, 78.1, 80.2, 82.8, 85.0, 87.5 (C1), 102.6 (C′1), 127.3, 127.4, 127.5, 127.6, 127.7, 127.9, 128.0, 128.1, 128.2, 128.3, 128.33, 128.4, 128.9, 132.1, 133.8, 138.2, 138.3, 138.4, 138.5, 138.6, 139.2. HRMS (ESI-TOF): calculated for C67H68O10SNa (M + Na) 1087.4431 and found 1087.4414.
:
1) to afford the compound 76 in 94% β as colourless syrup.33d Rf 0.35 (25% EA in hexane); 1H NMR (CDCl3, 300 MHz): δ 3.24 (m, 1H), 3.38–3.54 (m, 4H), 3.60–3.78 (m, 4H), 3.90 (dd, 1H, J = 3.2, 10.9 Hz), 4.04 (t, 1H, J = 9.5 Hz), 4.23 (dd, 1H, J = 4.9, 10.4 Hz), 4.45 (d, 1H, J = 11.9 Hz), 4.58–4.67 (m, 3H), 4.74–4.87 (m, 6H), 4.94 (d, 1H, J = 11.3 Hz), 5.01 (d, 1H, J = 10.7 Hz), 5.53 (s, 1H, PhCH), 7.27–7.61 (m, 35H, ArH). 13C NMR (CDCl3, 75 MHz): δ 62.4, 68.2, 70.7, 73.4, 74.9, 75.3, 75.5, 75.6, 76.6, 79.3, 82.5, 84.8, 87.5 (C1), 101.4 (PhCH), 102.6 (C′1), 126.1, 127.3, 127.5, 127.6, 127.7, 127.8, 127.9, 127.98, 128.2, 128.3, 128.4, 128.6, 128.9, 129.0, 129.7, 132.1, 138.2, 138.5. HRMS (ESI-TOF): calculated for C60H60O10SNa (M + Na) 995.3805 and found 995.3810.
:
1) to afford 79 (94%) as a white foam.22d Rf = 0.25 (30% ethyl acetate in hexane); [α]26D +16.3 (c 1.34, CHCl3); 1H NMR (600 MHz, CDCl3): δ 2.10 (s, 3H, COCH3), 3.53 (d, 1H, J = 9.6 Hz), 3.68 (m, 1H), 3.69 (m, 1H), 3.75 (dd, 1H, J = 3.0, 10.2 Hz), 3.87 (t, 1H, J = 9.6 Hz), 3.95 (dd, 1H, J = 3.6, 9.6 Hz), 4.00 (dd, 1H, J = 5.4, 10.8 Hz), 4.32 (d, 1H, J = 10.8 Hz), 4.36 (d, 1H, J = 12.0 Hz), 4.44 (d, 1H, J = 10.8 Hz), 4.50 (d, 1H, J = 10.8 Hz), 4.58 (d, 1H, J = 12.0 Hz), 4.81 (m, 1H), 4.84 (d, 1H, J = 10.8 Hz), 4.87 (d, 1H, J = 1.3 Hz, H′1), 5.36 (dd, 1H, J = 1.8, 3.0 Hz), 5.73 (d, 1H, J = 1.2 Hz, H1), 5.81 (dd, 1H, J = 3.0, 9.6 Hz), 5.94 (m, 1H), 5.99 (t, 1H, J = 10.2 Hz), 7.13–7.16 (m, 3H, ArH), 7.22–7.35 (m, 17H, ArH), 7.41–7.57 (m, 9H, ArH), 7.85 (d, 2H, J = 7.2 Hz, ArH), 8.00 (d, 2H, J = 7.2 Hz, ArH), 8.07 (d, 2H, J = 7.2 Hz, ArH). 13C NMR (150 MHz, CDCl3): δ 21.0, 66.6, 67.3, 68.44, 68.46, 70.45, 70.48, 71.5, 71.8, 72.0, 73.2, 74.0, 75.1, 78.4, 86.0 (C1) 98.0 (C′1) 127.50, 127.51, 127.7, 127.88, 127.90, 128.0, 128.18, 128.23, 128.27, 128.32, 128.4, 128.47, 128.54, 128.6, 128.9, 129.2, 129.3, 129.4, 129.71, 129.8, 129.74, 129.89, 129.9, 131.5, 132.1, 133.22, 133.25, 133.5, 133.6, 137.9, 138.0, 138.5, 165.3 (C
O), 165.4 (C
O), 170.3 (C
O); HRMS (ESI-TOF): calculated for C62H58O14SNa [M + Na]+ 1081.3445 found 1081.3441.
:
1) to afford 82 (92%) as a white foam. Rf = 0.25 (10% ethyl acetate in hexane); 1H NMR (300 MHz, CDCl3): δ 1.32 (d, 3H, J = 5.8 Hz, CH3), 1.36 (d, 3H, J = 6.1 Hz, CH3), 3.53–3.61 (m, 2H, H4, H′4), 3.89–3.93 (m, 2H, H3, H′5), 4.11–4.19 (m, 2H, H5, H′3), 4.25 (bs, 1H, H2), 4.62–4.69 (m, 3H, BnH), 4.73–4.76 (m, 2H, BnH), 4.85–4.99 (m, 3H, BnH), 5.12 (bs, 1H, H1), 5.51 (bs, 1H, H′1), 5.80 (bs, 1H, H′2), 7.24–7.64 (m, 28H, ArH), 8.13–8.15 (d, 2H, J = 7.1 Hz, ArH). 13C NMR (75 MHz, CDCl3): δ 18.0 (CH3), 18.1 (CH3), 68.5, 69.4, 69.5, 71.7, 74.4, 75.4, 77.8, 80.7, 80.1, 80.2, 87.3 (C1), 99.7 (C′1), 127.3, 127.6, 127.7, 127.8, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 129.1, 129.9, 130.1, 131.3, 133.2, 134.6, 138.1, 138.1, 138.4, 138.5, 165.6 (C
O).
:
1) on silica gel (230–400 mesh) to give 85 in 88% yield as colorless syrup. [α]27D −10.5 (c 1.2, CHCl3); lit.44 [α]24D −8.2 (c 0.98, CHCl3); 1H (300 MHz, CDCl3): δ 0.59 (d, 3H, J = 6.4 Hz, CH3), 2.23 (s, 3H, PhCH3), 3.45 (bs, 1H, H′4), 3.70 (m, 1H, H′5), 3.86–3.98 (m, 4H, H4, H5, H′2, H′3), 4.50 (d, 1H, J = 11.5 Hz, BnH), 4.61–4.86 (m, 8H, 5BnH, H1, H6, H′1), 5.06 (d, 1H, J = 10.9 Hz, H6), 5.23 (t, 1H, J = 9.7 Hz, H2), 5.69 (t, 1H, J = 8.9 Hz, H3), 6.86 (d, 2H, J = 8.0 Hz, ArH), 7.21–7.23 (m, 7H, ArH), 7.25–7.35 (m, 11H, ArH), 7.38–7.44 (m, 4H, ArH), 7.47–7.53 (m, 3H, ArH), 7.62–7.64 (m, 1H, ArH), 7.83–7.85 (d, 2H, J = 7.4 Hz, ArH), 7.88–7.91 (d, 2H, J = 7.3 Hz, ArH), 8.06–8.09 (d, 2H, J = 7.3 Hz, ArH). 13C NMR (75 MHz, CDCl3): δ 15.9, 21.1, 63.1, 67.7, 70.9, 72.7, 74.3, 74.8, 75.6, 75.7, 76.3, 77.2, 77.6, 77.8, 79.2, 85.5 (C1), 100.5 (C′1), 127.4, 127.5, 127.7, 128.1, 128.2, 128.3, 128.4, 128.41, 129.3, 129.5, 129.8, 129.9, 130.1, 133.0, 133.1, 133.9, 138.1, 138.3, 138.4, 138.6.
:
1) to afford 39 (196 mg, 87.3%) as a white foam. Spectroscopic data match with previous one and reported one.
:
1) to afford the title compound 88 as colorless syrup (93%); 1H NMR (CDCl3, 300 MHz): δ 3.19 (app t, 1H, J = 7.9, 9.1 Hz, H′2), 3.46 (m, 1H, H′5), 3.61 (s, 3H, OCH3), 3.68 (s, 3H, OCH3) 3.56–3.72 (m, 4H, H′3, H′4, H′6, H′6), 3.90 (dd, 1H, J = 8.4, 11.5 Hz, H6), 4.14–4.18 (m, 2H, H5, H6), 4.46 (d, 1H, J = 7.9 Hz, H′1), 4.52–4.62 (m, 3H, 3 × BnH), 4.78–4.97 (m, 4H, 3Bn × H, H1), 5.49 (t, 1H, J = 9.6 Hz, H4), 5.56 (t, 1H, J = 7.9 Hz, H2), 5.96 (t, 1H, J = 9.6 Hz, H3), 7.20–7.23 (m, 2H, ArH), 7.28–7.45 (m, 20H, ArH), 7.52–7.57 (t, 2H, J = 7.3 Hz, ArH), 7.86–7.88 (t, 2H, J = 7.6 Hz, ArH), 7.97–8.04 (m, 4H, ArH). 13C NMR (CDCl3, 75 MHz): δ 57.2, 60.5, 70.1, 72.0, 73.1, 73.5, 74.2, 74.8, 75.0, 75.6, 77.5, 84.2, 84.7, 102.0 (JC-H = 155.9 Hz, C′1) 104.1 (JC-H = 157.1 Hz, C1), 127.6, 127.7, 127.77, 127.82, 127.98, 128.01, 128.3, 128.39, 128.42, 128.5, 128.9, 129.4, 129.8, 129.9, 133.2, 133.5, 138.1, 138.2, 138.8, 165.2 (C
O), 165.4 (C
O), 165.9 (C
O).
:
1) on silica gel (100–200 mesh) to give 90 in 87% yield as colourless syrup. 1H (500 MHz, CDCl3): δ 1.60 (dt, 1H, J = 3.5, 12.5 Hz, H′2a), 2.23 (dd, 1H, J = 4.5, 12.5 Hz, H′2e), 3.29 (s, 3H, OCH3), 3.36 (dd, 1H, J = 3.5, 9.5 Hz), 3.45–3.49 (m, 2H), 3.54–3.62 (m, 3H), 3.71 (m, 1H), 3.91 (m, 1H), 4.01 (d, 1H, J = 9.5 Hz), 4.14–4.19 (m, 2H), 4.29 (d, 1H, J = 12.0 Hz, BnH), 4.42 (d, 1H, J = 11.0 Hz, BnH), 4.44 (d, 1H, J = 11 Hz, BnH), 4.51–4.60 (m, 5H, 4 × BnH, H′1), 4.79 (d, 1H, J = 11.0 Hz, BnH), 5.41 (d, 1H, J = 4.5 Hz, H1), 5.42 (s, 1H, PhCH) 7.07–7.37 (m, 25H, ArH). 13C NMR (CDCl3, 75 MHz): δ 35.4, 55.3, 61.9, 68.6, 70.7, 71.6, 72.7, 73.4, 73.7, 74.7, 77.4, 78.1, 78.3, 82.9, 97.6, 98.8, 101.4, 126.0, 127.3, 127.4, 127.5, 127.6, 127.7, 127.9, 128.1, 128.15, 128.2, 128.3, 128.4, 128.6, 129.0, 129.8, 134.5, 137.3, 137.7, 138.3, 138.9, 139.1.
Footnotes |
| † Electronic supplementary information (ESI) available. CCDC 1501233. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ra21859h |
| ‡ At present: Department of Organic Chemistry, IACS, Jadavpur, Kolkata 700032, India. |
| This journal is © The Royal Society of Chemistry 2016 |